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Abstract (298 words) 1 
Background: Associations of vitamin D with perinatal outcomes are inconsistent and few 2 
have considered the wider calcium metabolic system.  3 
Objective: To explore functional vitamin D deficiency in pregnancy by investigating 4 
associations between vitamin D status, parathyroid hormone and perinatal outcomes. 5 
Design: SCOPE (Screening for Pregnancy Endpoints) Ireland is a prospective cohort study of 6 
low risk, nulliparous pregnant women. We measured serum 25-hydroxyvitamin D [25(OH)D] 7 
and parathyroid hormone [PTH] at 15 weeks’ gestation in 1754 participants.  8 
Results: Mean ± SD 25(OH)D was 56.6 ± 25.8 nmol/L (22.7 ± 10.3 ng/mL) and geometric 9 
mean (95% CI) PTH was 7.84 (7.7, 8.0) pg/mL [0.86 (0.85, 0.88) pmol/L]. PTH was elevated 10 
in 34.3% of women who had 25(OH)D <30 nmol/L and in 13.9% of those with 25(OH)D ≥75 11 
nmol/L. While 17% had 25(OH)D <30 nmol/L, 5.5% had functional vitamin D deficiency, 12 
defined as 25(OH)D <30 nmol/L plus elevated PTH. Elevated mean arterial pressure (MAP), 13 
gestational hypertension, preeclampsia and small-for-gestational-age (SGA) birth were 14 
confirmed in 9.2%, 11.9%, 3.8% and 10.6% of participants, respectively. In fully adjusted 15 
regression models, neither low 25(OH)D nor elevated PTH alone increased risk of any 16 
individual outcome. The prevalence of elevated MAP (19.1% vs. 9.7%) and SGA (16.0% vs. 17 
6.7%) were highest (P <0.05) in those with functional vitamin D deficiency compared to the 18 
reference [25(OH)D ≥75 nmol/L and normal PTH]. The adjusted prevalence ratio (PR) and 19 
relative risk (RR) (95% CIs) for elevated MAP and SGA were 1.83 (1.02, 3.27) and 1.53 20 
(0.80, 2.93), respectively. There was no effect of functional vitamin D deficiency on the risk 21 
of gestational hypertension [adjusted RR (95% CI); 1.00 (0.60, 1.67)] or preeclampsia 22 
[adjusted RR (95% CI); 1.17 (0.32, 4.20)]. 23 
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Conclusions: The concept of functional vitamin D deficiency, reflecting calcium metabolic 24 
stress, should be considered in studies of vitamin D in pregnancy. 25 
Key words: Vitamin D, 25-hydroxyvitamin D, parathyroid hormone, pregnancy, perinatal, 26 






Pregnancy represents a period of particular nutritional vulnerability for the mother and 30 
developing fetus and nutritional deficits can adversely affect perinatal outcomes. Low 31 
vitamin D status [assessed by blood levels of 25-hydroxyvitamin D (25(OH)D)] in pregnancy 32 
is prevalent worldwide, in Caucasian and other ethnicities (1-3). Although low 25(OH)D has 33 
been associated with adverse perinatal outcomes including preeclampsia and small-for 34 
gestational-age (SGA) birth (4, 5), there is inconsistency in the literature (6). Vitamin D 35 
classically functions as part of the calcium metabolic system which maintains serum calcium 36 
within a critical narrow physiological window (7). Despite this long recognised metabolic 37 
connection, vitamin D and calcium are most often considered in isolation in terms of 38 
perinatal outcomes, with a lack of consideration for interactive effects (8). Although 39 
attenuated, the inverse relationship between 25(OH)D and calciotropic parathyroid hormone 40 
(PTH) is maintained in pregnancy in spite of the many changes in vitamin D and calcium 41 
metabolism (9). Secondary hyperparathyroidism refers to elevation of PTH resulting from 42 
low 25(OH)D and/or low calcium intake (10) and represents functional vitamin D deficiency.  43 
Scholl and colleagues described the concept of calcium metabolic stress in pregnancy, in 44 
which adverse effects of vitamin D deficiency are mediated through a functional impact on 45 
the calcium metabolic system (assessed by measurement of PTH) (11, 12). To the best of our 46 
knowledge, these associations have not been replicated in a large, well-characterized 47 
pregnancy cohort. We aimed to test the concept of calcium metabolic stress by exploring 48 
associations of 25(OH)D, PTH and functional vitamin D deficiency at 15 weeks’ gestation 49 
with adverse perinatal outcomes, including elevated mean arterial pressure (MAP), 50 
gestational hypertension, preeclampsia and SGA birth in a large cohort of low risk pregnant 51 
women.  52 
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Subjects and Methods 53 
Study design and participants 54 
The Screening for Pregnancy Endpoints (SCOPE) study (www.scopestudy.net), an 55 
international, multi-center, prospective cohort study was designed with the primary aim of 56 
developing screening tests to predict adverse pregnancy outcomes, with preeclampsia as the 57 
primary outcome variable (13). SCOPE Ireland recruited 1792 participants who were 58 
attending antenatal care at Cork University Maternity Hospital, Cork, Ireland (51.9°N) 59 
between March 2008 and February 2011. Full clinical and methodological study details have 60 
been published previously (13). In summary, nulliparous women were eligible for inclusion 61 
provided the pregnancy was a low risk singleton pregnancy at less than 16 weeks’ gestation. 62 
Exclusion criteria included pregnancies at increased risk of preeclampsia, SGA or 63 
spontaneous preterm birth due to specific underlying medical conditions or medical history, 64 
known major fetal anomaly or abnormal karyotype and interventions that could modify the 65 
outcome of pregnancy, such as aspirin treatment.  66 
Extensive data on family situation, lifestyle and demographics, including current smoking, 67 
alcohol and drug use, supplement use, activity, employment and medical history were 68 
collected by trained research midwives. As a pre-pregnancy measurement was not possible, 69 
and given the well-established systematic bias in self-report of weight and height, maternal 70 
height and weight at 15 weeks’ gestation were measured for calculation of BMI (14). Two 71 
consecutive blood pressure (BP) measurements were taken using a mercury or aneroid 72 
sphygmomanometer and proteinuria was assessed by semi-quantitative automated dip-stick 73 
reading. All demographic, anthropometric and clinical data were entered into a secure 74 
internet deployed database (MedSciNet AB, Stockholm, Sweden). Non-fasting blood samples 75 
were collected, processed to serum and stored at -80°C within 4 hours of collection. 76 
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SCOPE was conducted in accordance with the Declaration of Helsinki guidelines and ethical 77 
approval was obtained from the Clinical Research Ethics Committee of the Cork Teaching 78 
Hospitals [ECM5(10)05/02/2008]. SCOPE is registered at the Australian, New Zealand 79 
Clinical Trials Registry (http://www.anzctr.org.au), ID: ACTRN12607000551493. Written 80 
informed consent was provided by all participants at commencement of the study, which was 81 
on average, at 15 weeks of gestation. 82 
 
Clinical definition of outcomes 83 
Perinatal outcomes were precise and predefined (13), with participants followed 84 
prospectively throughout pregnancy and delivery. MAP was calculated from systolic and 85 
diastolic BP measurements as diastolic BP + [(systolic BP – diastolic BP)/3], with MAP > 90 86 
mmHg denoting elevated MAP. Gestational hypertension was defined as a systolic BP ≥ 140 87 
mmHg and/or diastolic BP ≥ 90 mmHg on at least two occasions four hours apart after 20 88 
weeks’ of gestation but before the onset of labor. Preeclampsia was gestational hypertension 89 
with either proteinuria (24 hour urinary protein ≥ 300 mg or spot urine protein:creatinine ratio 90 
≥ 30 mg/mmol creatinine or urine dipstick protein ≥ 2+) or any multi-system complication of 91 
preeclampsia. SGA birth was defined as a birth weight < 10th customized centile adjusted for 92 
maternal height, booking weight and ethnicity as well as gestation at delivery and infant sex 93 
(15).  94 
Biochemical Analysis 95 
Serum 25(OH)D 96 
Measurement of 25(OH)D in our laboratory has been detailed previously (16). Briefly, total 97 
25(OH)D was calculated by summation of individually quantified 25(OH)D2 and 25(OH)D3. 98 
Serum 25(OH)D2 and 25(OH)D3 concentrations were measured in using liquid 99 
chromatography-tandem mass spectrometry (LC-MS/MS) on a Waters Acquity UPLC 100 
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system coupled to an Acquity Triple Quadrupole (TQD)® mass spectrometer detector 101 
(Waters, Milford, USA). Four levels of serum-based NIST (National Institute of Standards 102 
and Technology) certified quality assurance material (SRM 972) were used for method 103 
validation while quality control materials assayed in parallel to all samples were purchased 104 
from Chromsystems (Munich, Germany). NIST calibrators (SRM 2972) were used 105 
throughout the analysis. The limit of detection (LoD) for 25(OH)D3 and 25(OH)D2 was 0.31 106 
and 0.44 nmol/L, respectively. The limit of quantitation (LoQ) for 25(OH)D3 and 25(OH)D2 107 
was 1.03 and 1.43 nmol/L, respectively. Intra- and inter- assay CVs for both metabolites were 108 
< 6% and < 5% respectively. The laboratory of the Cork Centre for Vitamin D and Nutrition 109 
Research is accredited by the CDC Vitamin D Standardization Certification program and 110 
participates in the Vitamin D External Quality Assessment Scheme (DEQAS) (Charring 111 
Cross Hospital, London, UK).  112 
Serum PTH 113 
Serum intact PTH was measured using an ELISA (MD Biosciences Inc., Minnesota, USA) on 114 
the automated Dynex DS2® ELISA processing platform (Dynex Technologies, Virginia, 115 
USA). This two-site assay is designed to measure biologically intact PTH 1-84 and utilizes 116 
two purified goat polyclonal antibodies, each specific to a distinct region on the PTH 117 
molecule. A biotinylated antibody binds to mid-region and C-terminal PTH 39-84. The 118 
detection antibody, a horseradish peroxidase conjugated antibody, binds N-terminal PTH 1-119 
34. PTH was measured in duplicate in 1497 participants and in singular in a further 257 120 
participants as serum volume was insufficient for duplicate measurement. Geometric mean 121 
PTH concentration did not differ between duplicate and single measurements (independent 122 
samples t-test, P = 0.10) and single and duplicate measurements were collated for analysis, 123 
giving a total of 1754 PTH measurements. Intra- and inter- assay CVs for intact PTH were < 124 
5% and < 7% respectively.  125 
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Statistical analysis 126 
Statistical analysis was performed using IBM SPSS® version 22.0 (IBM Corp., Armonk, NY, 127 
USA) and SAS® version 9.4 (SAS Institute Inc., Cary, NC, USA) software for Windows™. A 128 
full dataset, with no missing information, was available for all participants (n = 1754) and 129 
analysis was carried out without imputation. PTH was natural log-transformed to an 130 
approximately normal distribution and log PTH was used in analysis. Descriptive statistics 131 
were prepared for participants and independent samples t-test or ANOVA were used as 132 
appropriate to assess differences in mean concentrations of 25(OH)D and PTH within 133 
maternal characteristics. Post-hoc comparisons used Bonferroni correction. 25(OH)D is 134 
reported as mean ± SD and PTH as geometric mean (95% CI). The 25(OH)D/PTH 135 
relationship was graphically depicted by a scatter plot with Lowess curve (locally weighted 136 
regression smoothing scatterplot). ANOVA with Bonferroni corrected post-hoc analysis was 137 
performed to assess PTH concentrations across categories of 25(OH)D. Occurrence of 138 
adverse outcomes was compared between 25(OH)D/PTH categories using Chi-square tests 139 
(or Fisher’s test as appropriate). 140 
Associations between predictors and outcomes were assessed by log-Poisson regression, with 141 
regression models constructed to examine the effects of low 25(OH)D and elevated PTH, 142 
both individually and in combination, on adverse outcomes. While the full distribution of 143 
25(OH)D was explored, and 25(OH)D and PTH were described across the range of 25(OH)D 144 
values, we considered low vitamin D status as 25(OH)D < 30 nmol/L (7) and replete status ≥ 145 
75 nmol/L (17). These categories were used in regression models to allow simple comparison 146 
between groups of interest i.e. those with a low and replete vitamin D status. In the absence 147 
of pregnancy-specific reference ranges, we defined elevated PTH as greater than the 80th 148 
percentile. However, to minimize potential influence of undiagnosed pathological conditions 149 
relating to PTH, we excluded the top 2.5% of PTH concentrations. Thus, participants with 150 
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PTH between the 80th and 97.5th percentiles were classed as having elevated PTH. Reference 151 
groups were 25(OH)D ≥ 75 nmol/L and normal PTH (i.e. PTH ≤ 80th percentile). Non-white 152 
participants (n = 40) were excluded from regression models.  153 
Separate log-Poisson regression models (12 in total) were built for each predictor-outcome 154 
association based on both statistical goodness of fit of the model and clinical and theoretical 155 
knowledge. To circumvent the problem of large standard errors obtained with standard 156 
Poisson regression, we used Zou’s modified Poisson approach which leads to the estimation 157 
of robust error variance and produces correct confidence intervals (18). To obtain best fit 158 
models the following steps were taken. Univariable analysis was used to assess the 159 
association between each potential covariate and the outcome of interest, with inclusion 160 
based on significance at alpha = 0.25. A multivariable model including all significant 161 
covariates from the univariate analysis was constructed. The association of interaction terms 162 
with each outcome was examined, and interaction terms were included in multivariable 163 
models if significant (at alpha = 0.10) and clinically meaningful. To support the statistical 164 
model building process clinical and theoretical knowledge of established associations 165 
between variables along with directed acyclic graphs (DAGs) were used to develop a 166 
theoretical framework of covariate-predictor-outcome relationships and to determine the role 167 
of each covariate (e.g. confounder, intermediate, collider) in the model, aiding in decision 168 
making during model development. This process resulted in an individual best-fit log-Poisson 169 
regression model for each of the 12 predictor-outcome models. Although all associations 170 
were examined using the same modified log-Poisson approach detailed above, because 171 
25(OH)D, PTH and MAP were measured at the same time point associations are presented as 172 
prevalence ratios (PR) and 95% CIs while associations of 25(OH)D and PTH with gestational 173 





Descriptive results 177 
Participant characteristics and 25(OH)D and PTH concentrations in the SCOPE Ireland 178 
pregnancy cohort (n = 1754) are shown in Table 1. Mean ± SD 25(OH)D concentration was 179 
56.62 ± 25.8 nmol/L (22.7 ± 10.3 ng/mL) and geometric mean (95% CI) PTH was 7.84 (7.7, 180 
8.0) pg/mL [0.86 (0.85, 0.88) pmol/L]. This predominantly white (97.7%) cohort had a mean 181 
± SD age of 30.5 ± 4.5 years and BMI of 24.9 ± 4.2 kg/m2. At 15 weeks of gestation, 10.0% 182 
and 16.4% of participants, respectively, reported current smoking and alcohol consumption. 183 
Multi-nutrient supplements were consumed by 40% of participants and this was associated 184 
with significantly higher 25(OH)D and lower PTH concentrations in consumers (P < 0.001 185 
for both). White ethnicity was also associated with higher 25(OH)D and lower PTH than 186 
other ethnicities (P ≤ 0.001 for both). Although season of entry was significantly associated 187 
with 25(OH)D concentration (P < 0.001), PTH did not change with season. PTH increased 188 
and 25(OH)D decreased with increasing BMI category at 15 weeks of gestation; however 189 
post-hoc analysis revealed a significant decrease in 25(OH)D only in obese participants (BMI 190 
≥ 30 kg/m2) compared to those with a normal BMI. PTH concentration was highest in the 191 
small proportion of participants (1.2%) with a BMI < 18.5 kg/m2. Mean arterial pressure was 192 
79.1 ± 7.6 mmHg and 9.2% of participants had elevated MAP (> 90 mmHg). The prevalence 193 
of gestational hypertension, preeclampsia and SGA in the cohort were 11.9%, 3.8% and 194 
10.6%, respectively.  195 
Associations of 25(OH)D, PTH and functional vitamin D deficiency with perinatal 196 
outcomes 197 
The lowess curve in Figure 1 illustrates a decrease in PTH across a broad range of increasing 198 
25(OH)D concentrations, with a decline in rate of decrease evident between 40 - 50 nmol/L. 199 
Table 2 depicts PTH concentrations across the distribution of 25(OH)D, showing that PTH 200 
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decreased significantly with increasing 25(OH)D (P < 0.001). Elevated PTH occurred more 201 
commonly (P < 0.05) in participants with 25(OH)D < 30 nmol/L (34.3%) than those ≥ 75 202 
nmol/L (13.9%). In terms of vitamin D status, 44% of women had 25(OH)D < 50 nmol/L and 203 
17% were below 30 nmol/L, while 25% were had 25(OH)D ≥ 75 nmol/L. In the stratified 204 
analysis of 25(OH)D and PTH, the prevalence of functional vitamin D deficiency, defined as 205 
25(OH)D < 30 nmol/l plus PTH > 80th percentile, was much lower, at 5.5%, with 11.4% 206 
having a 25(OH)D < 50 nmol/L plus PTH > 80th percentile. 207 
Associations of 25(OH)D, PTH and 25(OH)D/PTH groupings with elevated MAP are shown 208 
in Table 3. The prevalence of elevated MAP was not significantly higher (12.0% versus 209 
9.3%) in participants with 25(OH)D < 30 nmol/L compared with 25(OH)D ≥ 75 nmol/L (P > 210 
0.05). While there was an association of elevated PTH with elevated MAP [PR (95% CI); 211 
1.49 (1.08, 2.04)], this trend was attenuated with covariate adjustment. Stratification of 212 
participants by 25(OH)D/PTH, shown in Table 3, revealed a prevalence of elevated MAP of 213 
19.1% in those with functional vitamin D deficiency compared with 9.7% in the reference 214 
group [25(OH)D ≥ 75 nmol/L and normal PTH] (P < 0.05), translating to an adjusted PR 215 
(95% CI) of 1.83 (1.02, 3.27). Prevalence of elevated MAP did not increase with 25(OH)D < 216 
30 nmol/L if PTH was not elevated [adjusted PR (95% CI); 0.91 (0.50, 1.65)]. 217 
Table 4 shows the associations of 25(OH)D, PTH and 25(OH)D/PTH groupings with 218 
gestational hypertension, preeclampsia and SGA birth. Having a 25(OH)D < 30 nmol/L 219 
increased the risk of SGA in crude but not adjusted analysis. There was no association of 220 
elevated PTH with gestational hypertension, preeclampsia or SGA. In combined 221 
25(OH)D/PTH groupings, the prevalence of gestational hypertension was highest with 222 
elevated PTH and did not vary with 25(OH)D (both 18%, P > 0.05). Having functional 223 
vitamin D deficiency did not increase risk of gestational hypertension compared to the 224 
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reference, which was 25(OH)D ≥ 75 nmol/L with normal PTH [adjusted RR (95% CI); 1.00 225 
(0.60, 1.67)].  226 
The lowest prevalence of preeclampsia (1.9%) was in those with 25(OH)D ≥ 75 nmol/L and 227 
normal PTH, compared to 5.0% when 25(OH)D ≥ 75 nmol/L with elevated PTH (P > 0.05). 228 
In those with 25(OH)D < 30 nmol/L, the prevalence of preeclampsia did not differ depending 229 
on PTH status (P > 0.05). Occurrence of preeclampsia was not significantly increased (4.3% 230 
versus 1.9%) with functional vitamin D deficiency compared to the reference group (P > 231 
0.05) [adjusted RR (95% CI); 1.17 (0.32, 4.20)].  232 
The proportion of participants with a SGA newborn in the reference group (6.7%) was lower 233 
than any other group, while 16% of those with functional vitamin D deficiency had a SGA 234 
birth (P < 0.05). A 2-fold increase in risk [RR (95% CI); 2.38 (1.31, 4.33)] was attenuated 235 
[adjusted RR (95% CI); 1.53 (0.80, 2.93)] in a fully adjusted model including BMI, smoking, 236 
university education, job status, recreational walking and multi-nutrient supplementation. A 237 
25(OH)D concentration ≥ 30 - < 75 nmol/L with elevated PTH was not associated with SGA 238 
or any other outcome (data not shown). Regression models were repeated for all outcomes 239 
using a 25(OH)D cut-off of < 50 nmol/L; no associations were observed in multivariate 240 
models (data not shown).  241 
 242 
Discussion 243 
Inconsistencies in associations of maternal vitamin D status and perinatal outcomes are 244 
multifactorial (4, 5, 19) but it is likely that calcium-vitamin D interactions, largely ignored, 245 
could be a critical consideration (8, 11, 12). In this largest study to date of 25(OH)D, PTH 246 
and pregnancy outcomes, we report a two-fold increased prevalence ratio of elevated MAP in 247 
women with functional vitamin D deficiency, defined by 25(OH)D < 30 nmol/L and elevated 248 
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PTH, versus those with 25(OH)D ≥ 75 nmol/L and normal PTH. This increase was present 249 
with low vitamin D status only if PTH was concurrently elevated. A similar trend was 250 
observed for SGA, although this was attenuated in regression models. Functional vitamin D 251 
deficiency did not increase risks of gestational hypertension or preeclampsia, although 252 
prevalence of preeclampsia was lowest, at 1.9%, in the reference group.  253 
Our analysis follows earlier analyses by Scholl et al (11, 12), who reported that women with 254 
functional vitamin D deficiency and calcium metabolic stress were two-three-fold more likely 255 
to develop preeclampsia and SGA. Mixed parity women recruited to their multi-ethnic (86% 256 
black or Hispanic) study were generally young (69% < 25 years of age) and of low 257 
socioeconomic status (11, 12). We aimed to extend the concept of functional vitamin D 258 
deficiency to a prospective cohort of well-characterized women in Northern Europe. 259 
Participants in the SCOPE Ireland cohort were nulliparous with low risk pregnancies, 260 
generally well-educated, mostly white and 89% were ≥ 25 years of age. In this cohort, as in 261 
the literature (20), clear differences in both 25(OH)D and PTH were evident between white 262 
and other ethnicities, highlighting the need for explorations of vitamin D and the calcium 263 
metabolic system that are specified by ethnicity. Thus, we restricted our current analysis to 264 
white participants as the numbers of other ethnic groups were too small to analyze separately.  265 
The prevalence of low vitamin D status in our cohort was higher than in many cohorts at 266 
similar latitude, reflective of the lack of a mandated maternal supplementation policy, 267 
analytical sensitivity and accuracy as well as inclement prevailing weather (16). Given that 268 
we previously observed a reduction in the combined prevalence of preeclampsia+SGA with 269 
25(OH)D ≥ 75 nmol/L (16) we chose this as the reference value for 25(OH)D and defined 270 
low 25(OH)D status as < 30 nmol/L (7). There is a lack of clarity with regard to PTH 271 
threshold levels in pregnancy, as PTH decreases in early gestation (21), reducing the 272 
applicability of non-pregnancy thresholds. In this context, and given the population specific 273 
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nature of PTH (22), as well as well-documented, substantial analytical differences between 274 
methods (23-27), we used a percentile cut-off, which although crude, may best capture 275 
elevated PTH at a sample specific level. Additionally, we excluded the top 2.5% of PTH 276 
values to minimise the risk of including undiagnosed cases of primary hyperparathyroidism, 277 
which may have produced artificially elevated outcome risks. Although sample specific, there 278 
may be some potential for misclassification of participants with use of a percentile cut-off as 279 
a result of inherent inter-individual variation in PTH. Concentrations of PTH were lower in 280 
our cohort than other studies (9, 11, 28, 29), but direct comparison is difficult; analytical 281 
method, gestation and ethnicity influence PTH, as do specimen type (30) and BMI (31). 282 
High PTH has been associated with blood pressure (32, 33) and cardiovascular risk indicators 283 
(34), and there are a number of biologically plausible mechanisms through which the calcium 284 
metabolic system may impact blood pressure. Belizán et al proposed that high PTH increases 285 
intracellular calcium, triggering contraction of vascular smooth muscle cells and 286 
vasoconstriction (35). Evidence of inter-play between the calcium metabolic system and 287 
renin-angiotensin-aldosterone system is accumulating (36). Hemodynamics can be explored 288 
through a range of measures and because a meta-analysis (n = 60,599) reported a second 289 
trimester MAP > 90 mmHg to be predictive of preeclampsia (37) we investigated this 290 
outcome in addition to gestational hypertension and preeclampsia. Although we report that 291 
those with functional vitamin D deficiency were two-fold more likely to have elevated MAP 292 
at 15 weeks’ gestation, there was no increase in risk of gestational hypertension. Given that 293 
25(OH)D, PTH and MAP were all measured at 15 weeks’ gestation, this may reflect a time-294 
point specific occurrence. Elevated MAP and gestational hypertension are not mutually 295 
inclusive outcomes; in this cohort 36% of those with elevated MAP at 15 weeks’ developed 296 
gestational hypertension and these outcomes may reflect different health profiles. Gestational 297 
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hypertension can occur at any stage in the second half of pregnancy and requires close 298 
monitoring and treatment as clinically indicated (38).  299 
Considering preeclampsia, the effect of vitamin D supplementation is not clear (19, 39). 300 
However, combined vitamin D and calcium supplementation significantly reduced risk of 301 
preeclampsia in three trials of 1,114 women (19). None of these trials compared each nutrient 302 
individually versus combined supplementation and placebo. In a cohort in which 6% 303 
developed preeclampsia, Scholl et al reported that participants with functional vitamin D 304 
deficiency at < 20 weeks’ gestation were three times more likely to develop preeclampsia 305 
(11). Despite a substantially larger sample size, we did not replicate this effect, potentially 306 
due to analytical differences and our application of a refined estimate of elevated PTH in a 307 
‘trimmed’ distribution. The inclusion criteria for SCOPE, focusing on women with low risk 308 
pregnancies, likely resulted in a different disease profile in those who developed 309 
preeclampsia between the two cohorts; a relevant consideration given potential differences in 310 
beneficial effects of vitamin D and calcium dependent on disease type and risk profile (40, 311 
41). However, the lowest prevalence of preeclampsia occurred in those with 25(OH)D ≥ 75 312 
nmol/L with normal PTH, indicating a potential benefit of higher serum 25(OH)D, as 313 
suggested by Aghajafari et al (4), particularly if PTH is not elevated. 314 
With regards to SGA, fetal skeletal development represents a potential mechanism through 315 
which perturbations in the maternal calcium metabolic system could predispose to SGA (42, 316 
43) and interactions between vitamin D and calcium on fetal bone growth have been noted in 317 
pregnant adolescents (44), a unique group due to dual growth requirements. Elevated blood 318 
pressure can also predispose to SGA birth, both in association with and independently of 319 
preeclampsia (45-47). Causative effects of vitamin D and calcium on fetal growth and SGA 320 
have not been definitively established (39, 41, 48, 49). Observational evidence suggests 321 
associations of both dairy intakes and PTH with fetal growth (50-52). A secondary analysis 322 
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of trial data in Gambian women, found no synergistic effect of calcium supplementation and 323 
25(OH)D on fetal growth (53). There was little evidence of vitamin D deficiency in the 324 
Gambian population who had low habitual calcium intakes, and these data may not be 325 
applicable in our setting with prevalent vitamin D deficiency. In our analysis we did not 326 
distinguish between SGA neonates born constitutionally small and those with fetal growth 327 
restriction resulting in SGA, in whom outcomes may be worse (54). 328 
To our knowledge, this is the largest study to investigate vitamin D and PTH in the context of 329 
pregnancy and perinatal outcomes. Our data are strengthened by use of clinically defined 330 
outcomes and the gold standard technique of CDC-accredited LC-MS/MS for measurement 331 
of 25(OH)D. However, we did not have access to calcium intake data; this would have 332 
enabled a more specific examination of calcium metabolic stress and perinatal outcomes, 333 
although inclusion of PTH may capture some variation resulting from differences in calcium 334 
intake. Harmonization and standardization of PTH analysis is required to define reference 335 
ranges for pregnancy and for the purposes of this field, to better describe the 25(OH)D/PTH 336 
relationship during gestation. In the absence of these data, the clinical significance of 337 
elevated PTH is difficult to interpret.  338 
In summary, prevalence of SGA was highest with functional vitamin D deficiency and we 339 
have demonstrated evidence of functional vitamin D deficiency and elevated MAP, reflecting 340 
the adverse impact of stress to the maternal calcium metabolic system in women at 15 weeks 341 
of gestation. Though challenging in design and resource allocation, consideration should be 342 
given to a priori inclusion of calcium intakes as well as quality-assured 25(OH)D and PTH 343 
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Table 1  
Sample characteristics, PTH and 25(OH)D concentrations in the SCOPE Ireland pregnancy 
cohort (n = 1754)1 








All participants   56.62 ± 25.8 -  7.84 (7.7, 8.0) - 
Ethnicity    < 0.001   0.001 
   White  97.7  57.11 ± 25.8   7.79 (7.6, 8.0)  
   Other 2.3  35.54 ± 19.9   10.28 (8.5, 12.5)  
Age (years)    < 0.001   0.15 
   < 25 11.5  49.38 ± 27.8   7.66 (7.1, 8.2)  
   ≥ 25 - < 30 30.3  58.47 ± 26.52   7.91 (7.6, 8.3)  
   ≥ 30 - < 35 45.0  57.88 ± 24.82   7.69 (7.4, 8.0)  
   ≥ 35 13.2  54.33 ± 24.8   8.38 (7.8, 9.0)  
BMI (kg/m2)3    0.017   0.0054 
   < 18.5 1.2  54.39 ± 29.0   9.77 (7.1, 13.5)  
   ≥ 18.5 - < 25 58.4  58.14 ± 26.3   7.58 (7.4, 7.8)  
   ≥ 25 - < 30 28.1  55.30 ± 25.2   8.14 (7.8, 8.5)  
   ≥ 30 12.3  52.62 ± 24.35   8.28 (7.7, 8.9)  
Smoking status3    < 0.001   0.08 
   No 90.0  57.66 ± 25.8   7.90 (7.7, 8.1)  




  0.10  
 0.47 
   No 83.6  56.17 ± 25.9   7.81 (7.6, 8.0)  







 < 0.001 
   No 60.1  48.70 ± 23.8   8.15 (7.9, 8.4)  
   Yes 39.9  68.54 ± 24.2   7.40 (7.1, 7.7)  





   Winter 58.4  49.54 ± 24.6   7.96 (7.7, 8.2)  
   Summer 41.6  66.57 ± 24.2   7.68 (7.4, 8.0)  
Elevated MAP3    0.42   0.10 
   No 90.8  57.28 ± 25.6   7.73 (7.5, 7.9)  
   Yes 9.2  55.61 ± 27.2   8.35 (7.6, 9.1)  
Gestational 
Hypertension 
   0.85   0.62 
   No 88.1  56.57 ± 25.8   7.82 (7.6, 8.0)  
   Yes 11.9  56.93 ± 26.1   7.99 (7.4, 8.7)  
Preeclampsia    0.18   0.28 
   No 96.2  57.27 ± 25.8   7.77 (7.6, 8.0)  
   Yes 3.8  52.97 ± 23.8   8.34 (7.3, 9.5)  
Small-for-
gestational-age 
   0.003   0.16 
   No 89.4  57.74 ± 26.0   7.75 (7.5, 7.9)  
   Yes 10.6  51.85 ± 23.3   8.20 (7.6, 8.9)  
1PTH, geometric mean (95% CI) (all such values); 25(OH)D, mean ± SD (all such values). 
Differences assessed using independent samples t-test for binary variables and ANOVA for 
variables with multiple categories. Post-hoc analysis used Bonferroni correction. PTH, 
parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D; SCOPE, Screening for Pregnancy 
Endpoints; MAP, mean arterial pressure. 
2P < 0.05 compared to lowest group.  
3At 15 week visit. 
4Overall ANOVA significant but no significant between group differences after Bonferroni 
correction. 
4P < 0.05 compared to BMI ≥ 18.5 - < 25 kg/m2. 










< 30 17.3 9.80 (9.2, 10.4)3,4 
≥ 30 - < 40 13.6 8.50 (8.0, 9.1)2,3,4 
≥ 40 - < 50 13.2 7.80 (7.3, 8.4)2,4 
≥ 50 - < 75 30.7 7.54 (7.2, 7.9)2,4 
≥ 75 25.2 6.78 (6.5, 7.1)2,3 
1PTH geometric mean (95% CI) (all such values). 
Differences assessed using ANOVA. Overall P-trend for 
ANOVA, P < 0.001. Post hoc analysis used Bonferroni 
correction. PTH, parathyroid hormone; 25(OH)D, 25-
hydroxyvitamin D; SCOPE, Screening for Pregnancy 
Endpoints. 
2P < 0.05 compared with < 30 nmol/L. 
3P < 0.05 compared with 50 - 75 nmol/L. 












Table 3  
Association of 25(OH)D and PTH with elevated MAP in white participants of the SCOPE 
Ireland pregnancy cohort1  





n % Unadjusted Adjusted 
≥ 75 — 441 9.3 Reference Reference 
< 30 — 283 12.0 1.29 (0.84, 1.99) 1.46 (0.90, 2.38)2 
— ≤ 80th 1338 9.3 Reference Reference 
— > 80th 334 13.8 1.49 (1.08, 2.04) 1.28 (0.94, 1.75)3 
      
≥ 75 ≤ 80th 373 9.7 Reference Reference 
≥ 75 > 80th 60 8.3 0.86 (0.35, 2.11) 0.89 (0.34, 2.28)4 
< 30 ≤ 80th 180 8.3 0.86 (0.49, 1.53) 0.91 (0.50, 1.65)4 
< 30 > 80th 94 19.1 1.98 (1.18, 3.33) 1.83 (1.02, 3.27)4 
1Values are PRs (95% CIs). Log-Poisson regression was used to examine the association 
between 25(OH)D and PTH thresholds (individually and in combination) and risk of elevated 
MAP. 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; MAP, mean arterial 
pressure; SCOPE, Screening for Pregnancy Endpoints. 
225(OH)D-MAP model adjusted for BMI, maternal age, university education and 
supplementation. 
3PTH-MAP model adjusted for BMI, maternal age, smoking, supplementation, recreational 
walking and alcohol consumption. 
425(OH)D/PTH-MAP model adjusted for BMI, maternal age, smoking, supplementation and 




Associations of 25(OH)D and PTH with gestational hypertension, preeclampsia and SGA in white participants of the SCOPE Ireland pregnancy 
cohort1  







% Unadjusted Adjusted 
 
% Unadjusted Adjusted 
 
% Unadjusted Adjusted 
≥ 75 — 441  14.3 Reference Reference  2.3 Reference Reference  7.3 Reference Reference 
< 30 — 283  12.7 0.89 (0.61, 1.30) 0.76 (0.51, 1.13)2  4.9 2.18 (0.98, 4.84) 1.06 (0.42, 2.68)3  13.1 1.80 (1.15, 2.82) 1.18 (0.70, 1.99)4 
— ≤ 80th 1338  11.3 Reference Reference  3.7 Reference Reference  10.3 Reference Reference 
— > 80th 334  14.7 1.30 (0.96, 1.75) 1.18 (0.87, 1.59)5  4.5 1.20 (0.68, 2.11) 1.13 (0.63, 2.00)6  10.8 1.05 (0.74, 1.48) 1.00 (0.71, 1.43)7 
               
≥ 75 ≤ 80th  373  13.7 Reference Reference  1.9 Reference Reference  6.7 Reference Reference 
≥ 75 > 80th  60  18.3 1.34 (0.74, 2.42) 1.24 (0.62, 2.50)8  5.0 2.66 (0.71, 10.02) 2.36 (0.68, 8.22)9  11.7 1.74 (0.79, 3.85) 1.72 (0.77, 3.88)10 
< 30 ≤ 80th  180  10.0 0.73 (0.44, 1.21) 0.61 (0.37, 1.02)8  5.0 2.66 (1.01, 7.04) 1.32 (0.45, 3.87)9  10.6 1.57 (0.89, 2.78) 0.97 (0.52, 1.81)10 
< 30 > 80th  94  18.1 1.32 (0.80, 2.18) 1.00 (0.60, 1.67)8  4.3 2.27 (0.68, 7.58) 1.17 (0.32, 4.20)9  16.0 2.38 (1.31, 4.33) 1.53 (0.80, 2.93)10 
1Values are RRs (95% CIs). Log-Poisson regression was used to examine the association between 25(OH)D and PTH (individually and in combination) and risk of gestational hypertension, 
preeclampsia and SGA. 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; SGA, small-for-gestational-age; SCOPE, Screening for Pregnancy Endpoints.  
225(OH)D-gestational hypertension model adjusted for BMI, smoking and recreational walking. 
325(OH)D-preeclampsia model adjusted for BMI, university education, and supplementation. 
425(OH)D-SGA model adjusted for university education, job status, supplementation and recreational walking. 
5PTH-gestational hypertension model adjusted for BMI, smoking, supplementation, moderate exercise and infant sex.  
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6PTH-preeclampsia adjusted for BMI, university education, supplementation, moderate exercise and infant sex. 
7PTH-SGA model adjusted for BMI, university education, job status, smoking and moderate exercise. 
825(OH)D/PTH-gestational hypertension model adjusted for BMI and recreational walking. 
925(OH)D/PTH-preeclampsia model adjusted for BMI, university education and supplementation. 




Figure 1. Scatterplot with Lowess curve of log parathyroid hormone and 25-hydroxyvitamin 
D in participants of the SCOPE Ireland pregnancy cohort (n = 1754).  
 
 
 
 
 
